You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《盈警响号》常茂生物(00954.HK)料去年未扣除减值等净利润降至最多3,400万人币
阿思达克 03-05 16:42
常茂生物(00954.HK)公布,集团很有可能录得截至去年12月31日止年度,在未考虑扣除其附属公司,连云港常茂的物业、机器及设备的减值损失及冲销递延税项资产前之综合净利润约2,700万元人民币(下同)至3,400万元,将较2019年度的综合净利润约5,829.9万元大幅下降。

集团指,主要由於去年初COVID-19疫情的爆发,导致客户需求减弱以及集团产品平均售价下降导致毛利率下降。为配合政府政策变更,公司必须关闭及搬迁位於常州受影响工厂区的某些生产线。集团於去年6月停止生产顺酐。在此之前,集团在常州一期厂房生产了部分供其他产品作原材料的的顺酐。自停止生产顺酐後,集团需全部从第三方购买顺酐。於去年第四季起,顺酐价格大幅上升;此外,集团不能够再循环利用顺酐生产过程中产生的蒸汽而得益。这些因素使得集团的生产成本增加,导致毛利率下降。

此外,去年集团预期将对连云港常茂的物业、机器及设备做出减值准备及部分递延税项资产予以冲销。为了配合连云港政府政策和集团的长远发展计划,集团将把连云港常茂的顺酐生产线搬迁到即将兴建的大连工厂。由於营运调整,将导致一些物业、机器及设备不能再使用以及部分有关结转税务亏损的递延税项资产将不可能实现。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account